Prognostic Factors for the Development of Biochemical Recurrence after Radical Prostatectomy by Ahmed F. Kotb & Ahmed A. Elabbady
Hindawi Publishing Corporation
Prostate Cancer
Volume 2011, Article ID 485189, 6 pages
doi:10.1155/2011/485189
Review Article
Prognostic Factors for theDevelopment ofBiochemical
Recurrence afterRadicalProstatectomy
Ahmed F.Kotband Ahmed A.Elabbady
Urology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Correspondence should be addressed to Ahmed A. Elabbady, a elabbady@hotmail.com
Received 28 February 2011; Revised 8 April 2011; Accepted 19 April 2011
Academic Editor: Kenneth A. Iczkowski
Copyright © 2011 A. F. Kotb and A. A. Elabbady. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Prostate cancer is one of the most common cancers in Western countries and is associated with a considerable risk of mortality.
Biochemicalrecurrence followingradical prostatectomy is a relatively commonﬁnding, aﬀecting approximately 25% of cases. The
aim of our paper was to identify factors that can predict the occurrence of biochemical recurrence, so the patient can be properly
counselled pre- and postoperatively. Medline review of the literatures was done followed by a group discussion on the chosen
publications and their valuable inﬂuence. Preoperative serum total PSA and clinical stage, together with prostatectomy Gleason
grade, tumour volume, and perineural and vascular invasions,were the most important variables found to inﬂuence outcome.
1.Introduction
In Canada, it is estimated that 1 in 7 men will develop
prostate cancer (Pca) during their lifetime, and 1 of 27 will
dieofit(aratioof1deathper4diagnosedcases)[1].In2009,
approximately 192.000 men from the USA were diagnosed
with prostate cancer, with an estimate of27.000ofthose men
dying from it [2].
The Food and Drug Administration (FDA) approved
PSA testing in 1986 to monitor men with prostate cancer.
Since then, PSA was widely used both to screen prostate
cancer and to monitor treatment response and recurrence.
This resulted in early diagnosis of cases with organ local-
ized disease amenable to deﬁnitive treatment and in early
diagnosis of disease recurrence following surgery with early
treatment before widespread dissemination.
The ideal therapy for clinically localized prostate cancer
is still controversial. Although radical prostatectomy (RP) is
a valid option, the rate of biochemical recurrence following
open or laparoscopic prostatectomy is estimated to be 15–
40% [3, 4].
As PSA may require up to 8 weeks to be cleared from the
circulation [5], biochemical recurrence cannot be diagnosed
before that time frame, following radical prostatectomy.
The American Urological Association and EAU deﬁned
biochemical recurrence (BCR) following RP as an initial
s e r u mP S Ao fg r e a t e rt h a no re q u a lt o0 . 2 n g / m L ,w i t ha
second conﬁrmatory level of PSA greater than 0.2ng/mL
[6,7]. Freedland et al. attemptedto deﬁnethe lowest PSAcut
point associated with PSA progression within 1 year, along
with 100% 3-year risk of progression [8]. They concluded
that a 0.2ng/mL represented the most conservative cut point
todeﬁneBCR,afterRP.Stephensonetal.subsequentlyexam-
ined the correlation between 10 deﬁnitions of biochemical
recurrence with metastatic progression in a clinical cohort
[9]. They proposed that biochemical recurrence should be
deﬁnedasaPSA>0.4ng/mLwithaconﬁrmatoryrise.Hattab
et al. deﬁned biochemical recurrence as two consecutive
serum PSA measurements >0.1ng/mL [10]. Regardless of
which deﬁnition may be better in deﬁning BCR, the aim is
to identify the perioperative factors associated with a high
risk of BCR, so that patients proved to be at a higher risk of
BCR can be followed more closely postoperatively and may
beadvisedforearlyadjuvanttreatment,afterRP.Croninetal.
studied 5473 patients, who underwent RP from 1985 to 2007
[11]. An analysis of perioperative clinical and pathological
parameters was done with 12 deﬁnitions of BCR. They
observed that the relative risks and hazard ratios were fairly
consistent between the 12 deﬁnitions examined, and the
statistical inference onestablished prognostic factors was not2 Prostate Cancer
impacted by the deﬁnition of BCR. So research groups using
diﬀerent deﬁnitions for BCR seem to reach similar conclu-
sions regarding prognostic factors.
We discuss some factors we believe to be of important
inﬂuence on the progression of prostate cancer, following its
deﬁnitive management.
2.PreoperativeFactors
2.1. Clinical Stage. The 2002 American Joint Committee
on cancer TNM clinical staging system for prostate cancer
substratiﬁed localized disease as T1 and T2. According to
this committee, T1 represents disease with no abnormality
on DRE and T2 represents a DRE palpable disease which is
furthersubclassiﬁedintoT2a,b ,andcaccor dingtotheextent
of prostatic lobes aﬀected [12]. D’Amico et al. developed
a risk stratiﬁcation system to predict BCR, after RP [13].
Both T1c and T2a were considered low-risk groups, whereas
T2b and T2c were classiﬁed as intermediate- and high-risk
groups, respectively. More recently, Billis et al. described
diﬀerent clinicopathological characteristics between patients
with clinical stage T1c versus stages T2a and T2b [14].
Freedland et al. also showed no diﬀerence in BCR rate
between patients with clinical stage T2a and T2b, with
excellent 10-year progression-free survival in both groups
[15].
Cooperberg et al. reported the San Francisco experience
in prostate cancer risk assessment [16]. They demonstrated
that clinical stage was not a predictive factor for biochemical
recurrence in their model. Armatys et al. conﬁrmed that
cases with cT2 had worse pathological outcomes than cT1c
[17]. However, no statistical diﬀerence between both groups
could be found regarding BCR rate. Reese et al. reported
that clinical stage in 4899 men who underwent RP for
localized Pca was predictive for BCR on univariate, rather
than multivariate, studies [18].
Stephenson et al. included clinical stage in their nomo-
gram to predict BCR following RP [19]. Hashimoto et
al. showed that clinical stage ≥T2a is highly signiﬁcant in
predicting positive surgical margin (SM) following RP [20].
In their cohort, positive SM was signiﬁcantly predicting a
higher rate of BCR, although they did not directly examine
the association between the clinical stage and the BCR. In
a study on Japanese populations, Egawa et al. found that
clinical stage contributed signiﬁcantly in the prediction of
biochemical recurrence, in their cohort of patients [21].
We conﬁrm DRE to be an integral part in the routine
urological examination, for men above 55 years of age.
Suspicious ﬁndings on DRE can predict worse outcomes
following deﬁnitive management, compared to cases where
diagnosis was based on high serum PSA with normal DRE
ﬁndings.
2.2. Preoperative Serum PSA and PSA Density (PSAd). PSA
and PSAd are factors predicting BCR in most of the available
nomograms and studies [16, 18, 22, 23]. Radwan et al.
reported that PSAd, whether measured using U/S or the true
prostate weight, was highly predicting for BCR, more than
PSA [23]. Freedland et al. [24] initially reported that PSAd
was a strong predictor for pathological adverse eﬀects and
BCR following RP and should be integrated in the risk strat-
iﬁcation for Pca. In a more recent study on a larger cohort
of patients, Freedland et al. found that preoperative PSAd
relative to PSA provides little improvement for predicting
BCR following RP [25]. Brassell et al. correlated PSA and
PSAd measured using both ultrasound and the true prostate
volume [26]. They reported that PSA was signiﬁcantly better
than PSAd in predicting BCR.
From our experience, we believe that PSAd has no
added role over PSA alone as a prognostic factor for disease
progression in intermediate- and high-risk groups (PSA
>10ng/mL). On the other hand, in low-risk groups, with
serum PSA <10ng/mL, PSAd is pivotal in predicting patient
outcome.
3.Pathological Factors
3.1. Gleason Grade. Gleason grade is the most widely ac-
cepted grading system for prostatic adenocarcinoma. Given
the inherent sampling error of diagnostic needle biopsy and
the multifocal nature of this tumor, discrepancy between
Gleason score (GS) of needle biopsy and RP specimen was
a common ﬁnding in the literature. King summarized 11
published series that covered over 2600 patients, in which
an accurate match of grading was seen in an average of
only 42% of the cases [27]. We thus believe that Gleason
grade obtained from needle biopsy has a limited role in the
decision making for patient management, compared to the
RP Gleason grading.
Gleason score 7 should not be considered in our opinion
as a single disease entity, and whenever the urologist is en-
countered with GS 7, decision on patient management
should be done based on its primary Gleason pattern. Lau
et al. studied 263 men with grade 7 RP specimens [28].
They noted that patients with primary Gleason grade 4 had
a signiﬁcantly higher rate of progression than patients with
primary Gleason grade 3 (46% versus 33%). Sakr et al.
performed the same study on 534 men, followed for a mean
of 34.6 months [29]. They showed that primary grade 4 was
associated with a higher rate of BCR, more than primary
grade 3 (23% versus 11%, at 2-year followup).
Some studies considered the percentage of high Gleason
pattern as a factor predicting a higher rate of BCR [30, 31].
On the other hand, Chan et al. reported that high Gleason
pattern is not likely to be reproducible [32]. It was often
diﬃcult and time consuming and results in a prognostic
eﬀect only at its extremes (greaterthan 70% or less than 20%
with pattern 4/5).
In our institution, we do not consider the percentage of
high Gleason pattern. Nevertheless, we follow the current
principals of considering cases with GS ≤6a sl o wr i s k ,
compared to cases with GS >6 as high risk.
3.2. Tumour Volume (TV). Data about the eﬀect of tumour
volume on BCR are contradictory in the literature. Some
studies could not ﬁnd a correlation between tumor volumeProstate Cancer 3
(TV) and BCR [33, 34], whereas others considered tumour
volume a high predictor factor for cancer progression [35–
39].
Fukuhara et al. used the maximum tumour diameter
(MTD) as an estimate for tumour volume, to correlate with
BCR [40]. They noted that, although both PSA and MTD
signiﬁcantly correlated with BCRonunivariate analysis, only
MTD independentlypredicted BCRon multivariate analysis.
These ﬁndings were in agreement with those of Chung et al.
[41].
In our institution, we prefer measuring the maximal
tumour diameter rather than the tumour volume. No data
is currently available for us to judge its direct eﬀect on the
rate of BCR. We believe it to be an important variable to be
included in our further studies.
3.3. Surgical Margin. Blute et al. reported a positive margin
rate of 39% in more than 2500 patients from the Mayo
series, and the BFS at 5 years was 67% and 84% in patients
with positive and negative SM, respectively [42]. Similarly,
Hashimoto et al. reported 5-year BFS rate of 62.6% and
81.7% for patients with positive and negative SM, respec-
tively [43].
Sæther et al. failed to show SM positivity to be an
independent risk factor for BCR although they could show
that it had a strong trend to do so (P = .06) [44].
Lake et al. studied the disease-free survival of patients
with negative surgical margin versus those with either focal
(FPM) or extensive positive surgical margin (EPM) [45]. In
their study, the 10-year DFS was 90%, 76%, and 53% for
those with negative SM, FPM, and EPM, respectively, and
that achieved statistical signiﬁcance. Ochiai et al. could also
show that patients with positive SM longer than 3 mm had
much lower outcomes than those with shorter positive SM
[46].
In our experience, a positive surgical margin is not a
factor toward a signiﬁcantly higher rate of BCR, although we
consider it an indication for adjuvant radiotherapy.
3.4. Perineural Invasion (PNI). A recent study from Italy
reported that 65.7% of their prostatectomy specimens that
were associated with higher Gleason grades had PNI, but
not BCR [47]. Merrilees et al. detected PNI in 90% of their
105 prostatectomy specimens [48]. They also concluded that
PNI was not a signiﬁcant predictor for the occurrence of
B C R .M i y a k ee ta l .f o u n dP N It ob eo fs i g n i ﬁ c a n c et op r e d i c t
BCRonunivariateanalysis butnotmultivariateanalysis[49].
Endrizzi and Seay found PNI in their 131 patients to be a
signiﬁcant factor predicting BCR, with a sensitivity of 82%
and a speciﬁcity of 57% [50].
Beard et al.studied theassociation of PNIand the relapse
rate following external beam radiation [51]. They reported a
signiﬁcant association of PNI with higher Gleason score and
a higher rate of BCR on univariate analysis. On multivariate
analysis, PNI was not an independent factor predicting BCR.
O’Malley et al. studied 78 patients with PNI detected by
prostatic biopsy with other 78 patients with absent PNI [52].
They reported no signiﬁcant eﬀectof PNI onthe rate ofBCR
following RP, when adjusted to GS, PSA, and pathological
stage.
3.5. Vascular Invasion (VI). Van den Ouden et al. reported
vascular invasion (VI) in 12% of their patients who under-
went prostatectomy [53]. VI was a signiﬁcant factor in
predicting BCR on univariate and multivariate analysis. De
la Taille et al. found VI in 12.4% oftheir cases and conﬁrmed
VI to be an independent signiﬁcant factor predicting BCR
[54]. Ferrari et al. detected VI in 18% of their patients and
conﬁrmed that VI was associated with worst pathological
outcomes and was an independent factor predicting BCR
on long-term followup [55]. The College of American
Pathologists recommended VI to be assessed routinely in
radical prostatectomy specimens [56].
3.6. Neuroendocrinal Diﬀerentiation. Quek et al. studied
the correlation between neuroendocrinal (NE) expression,
using CgA, in malignant and benign acini and recurrences
[57]. They detected statistically signiﬁcant association of the
number of NE cells in only malignant acini and clinical
recurrence. Weinstein et al. also showed that the number
of malignant NE cells is of prognostic signiﬁcance for pa-
tients undergoing radical prostatectomy [58]. In a multi-
variate analysis, May et al. [59] detected neuroendocrinal
diﬀerentiation to be the second most signiﬁcant predictor
for biochemical progression. On the other hand, other au-
thors did not ﬁnd a signiﬁcant association between NE
diﬀerentiationanddiseaseprogressionorbiochemicalfailure
[60, 61].
Although there are no solid data on the inﬂuence of
neuroendocrinal diﬀerentiation on BCR and although it is
currently not performed as a routine staining in our insti-
tution, we recommend staining for NE cells within the pros-
tate as this may serve to predict biochemical recurrence as
proposedbysome.Itmayalsopointtowardconsideringearly
chemotherapy in relapsing cases with higher degree of NE
diﬀerentiation.
4.Conclusion
There is wide consensus that biochemical recurrence occurs
in a large percentage of patients following successful radical
prostatectomy. No single factor can be considered toward
thepredictionofrecurrence. PreoperativePSA,clinicalstage,
prostatectomyGleasongrade,tumourvolume,perineuralin-
vasion, and vascular invasion are the most important clinical
and pathological parameters for assessing after radical pros-
tatectomy. Neuroendocrinal diﬀerentiation may be an im-
portant pathological criterion to look for in a prostatectomy
specimen.
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